Japanese Stocks With Strong Cash Flow That Look Cheap Today

Euro area private sector credit growth is picking up, which points to easier borrowing conditions and fresh fuel for companies with healthy finances. That creates a window in which high quality businesses can invest for the next leg of growth while their share prices still appear out of favour. This article looks at three stocks from the High Quality Undervalued Stocks screener that match that profile.

The stocks highlighted below are a starting sample from this idea. The full screen surfaced 23 more companies with similarly compelling risk and return profiles that are not covered here. To identify and analyze the highest conviction opportunities, go straight to the High Quality Undervalued Stocks screener.

Chugai Pharmaceutical (TSE:4519)

Overview: Chugai Pharmaceutical is a Japan based drug developer focused on high value biologic and oncology therapies such as Alecensa, Actemra, Vabysmo and Hemlibra, many of which are partnered with Roche. These marketed biologics help generate cash flows that support a broader portfolio across autoimmune, rare diseases, infectious disease and other therapeutic areas.

Operations: Chugai generates all of its ¥1,342,809 million pharmaceutical revenue from its Pharmaceuticals segment, with ¥486,188 million reported in Japan and the remainder captured within segment adjustments that reflect its wider international reach.

Market Cap: ¥11,429.9 billion

Chugai Pharmaceutical provides exposure to an established biologics and oncology portfolio that supports cash generation and an R&D engine, with recent half year revenue of ¥663,331 million and net income of ¥231,749 million. Flagship drugs such as Hemlibra, Actemra and Vabysmo help anchor the High Quality Undervalued Stocks theme by backing that pipeline with cash flows and a solid balance sheet, while the new AI partnership with Phylo aims to make future drug discovery more efficient. The risk is clear, though. Dependence on a handful of blockbuster products, regulatory pricing pressure and reliance on Roche can all affect future earnings. For investors willing to weigh those trade offs, Chugai’s mix of quality assets and underappreciated potential may merit closer examination.

Chugai Pharmaceutical’s cash rich biologics portfolio and AI enabled R&D push are easy to overlook when focus sits on a few blockbuster drugs. Get the full context and see how the 3 key rewards and 1 important warning sign.

Recruit Holdings (TSE:6098)

Overview: Recruit Holdings is a Tokyo based HR and business solutions company. Its HR Technology segment runs global online job platforms like Indeed type sites and Japanese job portals that connect employers with candidates and earn recurring fees and advertising revenue. Its Staffing and Marketing Matching businesses provide temporary staffing and online marketplaces for services such as beauty, travel, dining and real estate.

Operations: Recruit Holdings generates ¥1,750,504 million from Staffing, ¥1,572,067 million from HR Technology and ¥569,700 million from Marketing Matching Technologies, with a ¥28,409 million unallocated adjustment.

Market Cap: ¥23,625.1 billion

Recruit Holdings may appeal to investors seeking exposure to HR platforms with recurring revenue and strong cash conversion, while also valuing diversified earnings from staffing and marketing solutions. HR Technology is the key link to the High Quality Undervalued Stocks theme, with guidance raised in August 2026 after that segment outperformed and lifted full year revenue and profit targets. At the same time, management is trimming costs, investing in automation and AI and returning capital through buybacks, which together support the quality angle. Potential constraints include softer job demand, slower adoption of new services such as Indeed PLUS and reliance on external funding, which can all affect how quickly that quality profile translates into sustained value for shareholders.

Recruit Holdings’ HR platforms, cost cuts and AI investment hint at a business that may be quietly resetting its earnings power. See how the analyst forecasts for Recruit Holdings ties that story together and what could still trip it up.

Murata Manufacturing (TSE:6981)

Overview: Murata Manufacturing is a Japanese electronics company that supplies high volume multilayer ceramic capacitors and RF modules for smartphones, cars and data centers, alongside a broad range of other passive components, sensors and batteries used across communications, industrial and energy applications.

Operations: Murata generates ¥1,250,550 million from Components and ¥664,774 million from Devices and Modules, with only ¥71,492 million from Others, while its end markets and customers are spread globally across Japan, the Americas, Europe, Greater China and the rest of Asia.

Market Cap: ¥13,304.5 billion

Murata Manufacturing may merit a closer look for investors seeking exposure to the electronic components used in mobility and communications while aiming to avoid significant balance sheet risk. Its high volume MLCC and RF component business is a key cash engine, supported by raised full year guidance and dividend payouts that indicate solid free cash flow generation. At the same time, demand is linked to the semiconductor and electronics cycle, so periods of weaker smartphone or auto orders can affect earnings and contribute to share price volatility. For investors prepared to navigate those swings, the combination of core cash generation, global reach and an undervaluation signal highlights that there may be more to Murata’s story than the current share price reflects.

Murata Manufacturing’s cash engine in components and RF modules may be masking a much bigger story in its global reach and balance sheet strength. Get the full picture in the analysis report for Murata Manufacturing

Seeking Alternatives Before The Crowd Moves

Fresh ideas can move first when momentum builds and breakouts start flying under most radars. Scan these curated stock lists before the crowd catches on and prices start dropping, act now.

• Spot resilient businesses that may be built to ride through shocks and still keep their balance sheets in shape with a focused list of solid balance sheet and fundamentals (41 results).
• Target early stage miners that may be positioned for potential metals momentum using a curated set of 34 elite gold producer stocks that could slip away once attention floods in.
• Track companies that may be building the digital backbone for AI growth through a concentrated pool of 55 AI infrastructure stocks before that story is fully reflected in prices.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com